Document is current

Any future updates will be listed below

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Crossref DOI link: https://doi.org/10.1007/s10637-014-0177-3

Published Online: 2014-10-22

Published Print: 2015-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark